Riociguat (BAY63-2521)

DRUG4 trials

Sponsors

Bayer

Conditions

Coronary Artery DiseaseHypertension, PulmonaryPharmacology, ClinicalVentricular Dysfunction, Left

Phase 1

Relative Bioavailability and Food Effect Study

CompletedNCT01489488

BayerPharmacology, Clinical

Start: 2012-01-31End: 2012-05-31Updated: 2015-07-01

Phase 2

Coronary Vasomotor Response After Riociguat Exposure

WithdrawnNCT01165931

BayerCoronary Artery Disease

Start: 2012-05-31End: 2013-01-31Updated: 2013-10-23

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction

TerminatedNCT01172756

BayerHypertension, Pulmonary, Ventricular Dysfunction, Left

Start: 2010-07-31End: 2012-10-31Updated: 2014-11-04

Phase 3

BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension

CompletedNCT00863681

BayerHypertension, Pulmonary

Start: 2009-03-12End: 2019-08-19Updated: 2023-11-07

Related Papers

Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

2021-07-1014 citations

Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.

2016-07-2588 citations

Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.

2016-04-0880 citations

Population Pharmacokinetics and the Pharmacokinetic/Pharmacodynamic Relationship of Riociguat in Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension

Pulmonary Circulation2016-03-0114 citations

Riociguat for pulmonary arterial hypertension associated with congenital heart disease

Heart2015-07-01110 citations

Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study.

2014-11-01190 citations

Riociguat for the Treatment of Pulmonary Arterial Hypertension

New England Journal of Medicine2013-07-241309 citations